Neurocrine Biosciences Inc (NBIX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $16.94B
Last updated: Nov 17, 2026 at 11:05 AM ET
Neurocrine Biosciences Inc (NBIX) Stock Forecast
Analysts expect Neurocrine Biosciences (NBIX) to earn $10.59 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.99B. Of 29 analysts, 25 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 29 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 13.8% |
| Buy | 21 | 72.4% |
| Hold | 4 | 13.8% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 29
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 16.1% and revenue estimates rise 14.8%.
- Fiscal year ending Dec 31, 2026
- $10.59
- EPS consensus, revenue $3.99B
- Fiscal year ending Dec 31, 2027
- $12.30
- EPS consensus, revenue $4.58B
- Next report
- Feb 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $10.59 | $9.35 to $12.39 | 16 | $3.99B | $3.91B to $4.18B | 23 |
| Dec 31, 2027 | $12.30 | $9.36 to $16.22 | 16 | $4.58B | $4.37B to $5.07B | 25 |
Quarterly Estimates
The EPS consensus rises from $2.02 for the quarter ending Dec 31, 2026 to $2.73 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.02 | $1.34 to $2.56 | 29 | $1.11B | $1.03B to $1.26B | 27 |
| Mar 31, 2027 | $2.73 | $2.32 to $3.11 | 6 | $1.07B | $1.03B to $1.09B | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 7 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 4 |
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.1% from $10.17.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $10.59 | $10.24 | $10.21 | $10.20 | $10.17 | +4.1% |
| Fiscal year ending Dec 31, 2027 | $12.30 | $11.74 | $11.88 | $11.97 | $12.17 | +1.0% |
| Quarter ending Mar 31, 2027 | $2.73 | $2.74 | $2.65 | $2.65 | $2.65 | +2.9% |
Frequently Asked Questions About NBIX
What is the NBIX stock forecast?
Consensus analyst estimates put Neurocrine Biosciences's EPS at $10.59 for the fiscal year ending Dec 31, 2026, on revenue of $3.99B. The consensus rating from 29 analysts is Buy.
How do analysts rate NBIX stock?
Of 29 analysts covering Neurocrine Biosciences, 4 rate it Strong Buy, 21 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NBIX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $10.59, with estimates from $9.35 to $12.39 from 16 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $12.30, with estimates from $9.36 to $16.22 from 16 analysts.
What revenue do analysts expect from Neurocrine Biosciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.99B, with estimates from $3.91B to $4.18B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.58B, with estimates from $4.37B to $5.07B.
How many analysts cover NBIX?
29 analysts rate Neurocrine Biosciences stock, and 16 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NBIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors